Pneumococcal infections are a major cause of morbidity and mortality worldwide.
Pneumococcal conjugate vaccines represent major progress in the prevention of invasive …

Background: Meta-analyses enable summarization and interpretation of data across clinical
trials. When applied to safety data they allow for detection of rare events. Recently, a 13 …

Introduction The invasive pneumococcal diseases (IPDs) caused by Streptococcus
pneumoniae pose an enormous threat to children under 5 years of age. However, routine …

Safety and immunologic non-inferiority of 13-valent pneumococcal conjugate vaccine given
as a 3-dose series with routine vaccines in healty children/Esposito, S.; Tansey, S.; …

Background Pneumococcal diseases among children aged< 5 years worldwide are
associated with high annual mortality rates. Purpose This study aimed to evaluate the …

Background: The global distribution of pneumococcal disease and emergence of
nonvaccine pneumococcal serotypes prompted the development of a 13-valent …

Importance Immunization schedules with pneumococcal conjugate vaccine (PCV) differ
among countries regarding the number of doses, age at vaccinations, and interval between …

To evaluate the safety of the 15-valent pneumococcal conjugate vaccine (PCV15 (by LvZhu
& Co. Ltd)) in healthy infants aged 2 months (minimum to 6 weeks) and 3 months old. This …

Background Several studies have shown differences in susceptibility to infections and
immune response to vaccines by sex. Prematurely born infants are at higher risk for …

Background: Pneumococcal disease remains a public health priority worldwide. This phase
2 study (V114-008; NCT02987972; EudraCT 2016-001117-25) compared safety and …